Bluegrass Vascular Technologies (BVT)
The private medical technology company hails Dr. Gabriele Niederauer as the new President and CEO. Niederauer is a distinguished senior medical device executive, who brings more than 20 years experience in the development and commercialization of medical devices to the position.
Prior to BVT, Niederauer served as Vice President of R&D for ArthroCare Corporation, ENT-Sinus Division, where she had an active role in developing and commercializing novel implants for sinus surgery. She also held senior roles at ENTrigue Surgical, C2M Medical and OsteoBiologics.
Former CEO and Co-founder Jim Clifton will now serve as Chief Operating Officer and will be responsible for company operations, project management and market strategy.
Dimension Therapeutics
The gene therapy company welcomes Annalisa Jenkins, MBBS, MRCP, as their new Chief Executive Officer. Preceding Dimension, Jenkins served as Executive Vice President for Merck Serono, where she led global medical affairs.
Jenkins possesses nearly 20 years of dynamic experience in the industry in building teams that have advanced from the infancy stages of scientific research and clinical development through regulation and approval for the global healthcare systems. Also, while at Bristol Myers-Squibb, Jenkins made major contributions to a number of their key pipeline programs.
Chairman and Co-founder Ben Auspitz says, “Annalisa is a passionate and energetic leader with a proven track record of successfully translating exciting science from the bench to the bedside.”
Afferent Pharmaceuticals
Kathleen Sereda Glaub, who recently served as an independent member of Afferent’s board, has been appointed as the company’s Chief Executive Officer. She brings 30 years of leadership experience to the position and served as president for Plexxikon Inc., where she was responsible for the company’s venture and partnership transactions.
Agilis Biotherapeutic, LLC
The synthetic biology-based company named Dr. Mark J. Pykett, President and CEO. Dr. Pykett has a very accomplished career in the biotechnology, pharmaceutical and healthcare industries, with 20 years of experience. Prior to Agilis, he most recently served as the president and Chief Executive Officer for Navidea Biopharmaceuticals.
Aptose Biosciences, Inc.
Stephen B. Howell, MD a renowned medical oncologist, has been recruited to act in the capacity of Chief Medical Officer for Aptose. Howell is a leader in drug development and serves as a Distinguished Professor of the Medical Division of Hematology-Oncology at the University of California, San Diego Moores Cancer Center.
Array BioPharma, Inc.
Victor Sandor, MD has been named Chief Medical Officer for the biopharmaceutical company. As Chief Medical Officer, Dr. Sandor will be responsible for leading medical and regulatory strategy and operations for the company. Throughout his career, Dr. Sandor has had many successes in clinical development and marketing products for Incyte, Biogen and AstraZeneca.
Astellas
James Kellerman has been appointed as Vice President of Intellectual Property (IP) in the Americas for Astellas, where he will lead a team of patent lawyers and manage the regions’ intellectual property matters. Kellerman worked in the IP department of GlaxoSmithKline. Christy Noland was also appointed as Director of Business Communications & Advocacy, Urology in the Americas. Most recently, she served as the director of communications for the renal business at Baxter International Inc.
Cardinal Health
Cardinal Health named Michael C. Kaufmann as their company’s Chief Financial Officer. Kaufmann has been with Cardinal Health for 24 years, and in that time he has held numerous finance positions within the company. Since 2009, he has served as the Chief Executive Officer for the company’s pharmaceutical segment.
Coherus BioSciences
The late-stage biologics platform company recently appointed Mary Szela to its board of directors. Szela is currently CEO of Melinta Therapeutics, Inc. Her record includes a 25-year history of generating growth, creating positive organizational change and inspiring high performing teams.
[Insert Drew Young to Jeffrey W. Ubben image here]
EMD Serono, Inc.
Drew Young, formerly of Biogen Idec, Inc., will be joining EMD Serono, a Merck KGaA subsidiary, as the company’s new Senior Vice President of Neurology and Immunology. Young brings over 20 years of experience in marketing and sales for pharmaceutical and biotechnology companies to his new position.
Nabriva Therapeutics AG
Nabriva Therapeutics, a biotechnology company responsible for the development of drugs to treat serious infections, names Dr. Colin Broom as their new Chief Executive Officer. Dr. Broom is a veteran in the industry with 30 years experience in biopharmaceutical drug development and commercialization. Most recently, he worked as the Chief Scientific Officer at ViroPharma, Inc.
Nurix, Inc.
Arthur T. Sands, MD, PhD, has been named Chief Executive Officer of Nurix. Sands co-founded Lexicon Pharmaceuticals and served as the company’s President, Director and Chief Executive Officer. Pierre Beaurang, PhD, will serve with Sands as the Vice President of Business and Corporate Development.
Pivotal Therapeutics, Inc.
Pivotal Therapeutics appointed an exciting new addition to their company. Prakash Gowd is now the Chief Financial Officer. Gowd has an impressive history in the world of investment banking where he is a top-ranked leading healthcare equity analyst. Most recently, Gowd served as a Managing Director at a leading Canadian bank.
Thesan Pharmaceuticals
Welcomes Bhaskar Chaudhuri, PhD, to their board of directors. Chaudhuri possesses more than 25 years experience in pharmaceutical management, drug research and development and the commercialization of drugs in the U.S. and EU markets. Most recently, he served as President of Valeant Pharmaceuticals and Operating Partner at Frazier Healthcare.
Valeant Pharmaceuticals
Jeffrey W. Ubben is now a member of Valeant Pharmaceutical’s Board of Directors. Ubben founded ValueAct Capital in 2000. Since then he has served as Chief Executive Officer and Chief Investment Officer of the company. Most recently, Ubben served as a Managing Partner at Blum Capital Partners.
Xencor, Inc.
The clinical-stage biopharmaceutical company elected Debra Zack, MD, PhD, as the new Vice President of Clinical Development. Lloyd Rowland will serve as the company’s Senior Vice President, Chief Compliance Officer and General Counsel.
